Le Lézard
Classified in: Health
Subject: PER

Avelas Biosciences Broadens Management Team with Key Executive Additions



SAN DIEGO, Jan. 3, 2018 /PRNewswire/ -- Avelas Biosciences, Inc., a clinical stage oncology-focused company that is developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention, today announced three new management appointments.  The additions to the Avelas executive team include Kyri Van Hoose as Vice President, Finance, Kenneth Kleinhenz as Vice President, Regulatory Affairs and Quality Assurance, and Ning Zou, Ph.D., as Principal Scientist, Head of Chemistry.

"We are delighted to announce these key appointments to the Avelas leadership team, which will help us to catalyze our next phase of growth and execute further on our strategic initiatives," said Carmine Stengone, President and Chief Executive Officer of Avelas Biosciences.  "Each individual brings a unique array of talents that I know we can leverage as we advance our platform and expand our pipeline through data readouts, additional studies and partnering activities."

Kyri Van Hoose joins Avelas as Vice President, Finance, bringing with her over 15 years of experience, predominantly in the life science industry.  Prior to joining Avelas, Ms. Van Hoose held a series of accounting, finance and business development positions of increasing responsibility over a period of 10 years at ACADIA Pharmaceuticals, Inc.  Before ACADIA, Ms. Van Hoose gained experience in the life science industry with Invitrogen, Inc. and Allergan plc.  Ms. Van Hoose began her career with Deloitte and is a licensed Certified Public Accountant in the state of California.  Ms. Van Hoose earned her B.S. in accounting from the University of Southern California and her MBA from the University of California, Irvine.

Kenneth Kleinhenz joins Avelas as Vice President, Regulatory Affairs and Quality Assurance, and brings with him more than 25 years of experience in FDA-regulated medical device manufacturing, medical device research and development, and clinical settings.  Prior to joining Avelas, Mr. Kleinhenz was Vice President of Regulatory Affairs and Quality Assurance at Cytori Therapeutics. Before Cytori, Mr. Kleinhenz served as Senior Director of Regulatory Affairs and Quality Assurance at MacroPore Biosurgery.  Previously Mr. Kleinhenz held positions with IFM Manufacturing, Becton Dikinson and Pacific Pharmaceuticals.  Mr. Kleinhenz received his MBA from the University of Phoenix and a B.S. in microbiology from University of California, San Diego.

Ning Zou, Ph.D., joins Avelas as Principal Scientist, Head of Chemistry, and brings over 15 years of experience in drug discovery to Avelas.  Prior to joining Avelas, Dr. Zou held roles of increasing seniority and responsibility at Endocyte, most recently as Senior Director, Chemistry.  Dr. Zou previously worked at Ambrx and Arena Pharmaceuticals.  Dr. Zou was a Postdoctoral Research Associate at The Scripps Research Institute, a Postdoctoral Fellow at Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, and a Research Assistant at The University of Hong Kong.  Dr. Zou earned his Ph.D. in synthetic organic chemistry from Lanzhou University, China.

About Avelas Biosciences

Avelas Biosciences is a San Diego-based biotechnology company focused on developing products to advance a new standard-of-care for cancer surgery and therapeutic intervention.  The company's lead candidate, AVB-620, has completed a Phase 1b clinical trial assessing safety, pharmacokinetics and fluorescence properties using tissue image analysis.  A Phase 2 clinical trial for AVB-620 in breast cancer is ongoing.  In addition, the company is advancing a therapeutic program, which utilizes the same technology platform.  Avelas was founded on technology from Roger Y. Tsien, Ph.D., co-winner of the 2008 Nobel Prize in chemistry.  For additional information, please visit www.avelasbio.com.

 

SOURCE Avelas Biosciences, Inc.


These press releases may also interest you

at 01:54
APRINOIA Therapeutics Inc., a clinical-stage neuroscience biotech company, focuses on tau, alpha-synuclein, and novel targets for neurodegenerative diseases, announces today the completion of its US$11.1 million Series B round. The Series B round was...

at 01:21
Novartis announced today results from the head-to-head CLARITY study demonstrating the superiority of Cosentyx® (secukinumab) compared to Stelara® (ustekinumab) in delivering clear and almost clear skin in adults with moderate to severe plaque...

at 01:20
Sandoz, a Novartis division and the global leader in biosimilar medicines, announced today that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA), submitted under the 351 (k) pathway, for proposed...

15 jan 2018
Therap is offering interactive workshops for its National Conference attendees from the state of Nebraska providing community based services to individuals with intellectual and developmental disabilities that receive funding from the State of...

15 jan 2018
The health and safety of more than 520,000 Rohingya children living in overcrowded camps and informal settlements in Bangladesh is likely to be put at even greater risk ahead of upcoming cyclone and monsoon seasons, UNICEF warned today. "As we...

15 jan 2018
Today, the Canadian Medical Association Journal Open published a study from the University of Waterloo entitled, Adverse effects of caffeinated energy drinks among youth and young adults in Canada: a Web-based survey. The Canadian Beverage...




News published on 3 january 2018 at 11:30 and distributed by: